We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

39 hedge funds and large institutions have $191M invested in Acrivon Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

733% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 3

117% more funds holding

Funds holding: 18 → 39 (+21)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

12% more capital invested

Capital invested by funds: $170M → $191M (+$20.7M)

2.22% less ownership

Funds ownership: 71.64% → 69.42% (-2.2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
39
Holders Change
+21
Holders Change %
+116.67%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
6
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.87M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.95M
4
State Street
State Street
Massachusetts
+$1.43M
5
Northern Trust
Northern Trust
Illinois
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$10.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$3.52M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$545K
4
Goldman Sachs
Goldman Sachs
New York
-$421K
5
Two Sigma Investments
Two Sigma Investments
New York
-$248K
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
26
MetLife Investment Management
New Jersey
$64.5K +$85.3K +5,081 New
AIG
27
American International Group
New York
$53K +$70.2K +4,178 New
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$40.8K +$54K +3,218 New
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$28K +$37K +2,206 New
SO
30
STRS Ohio
Ohio
$22K +$30.2K +1,800 New
Wells Fargo
31
Wells Fargo
California
$20.2K +$26.7K +1,588 New
TRCT
32
Tower Research Capital (TRC)
New York
$14K +$15.7K +933 +587%
AB
33
Amalgamated Bank
New York
$14K +$19K +1,130 New
Legal & General Group
34
Legal & General Group
United Kingdom
$11.7K +$15.5K +924 New
AIP
35
Ameritas Investment Partners
Nebraska
$8.82K +$11.7K +695 New
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$8K +$11.2K +665 New
MLICM
37
Metropolitan Life Insurance Company (MetLife)
New York
$6.64K +$8.78K +523 New
Citigroup
38
Citigroup
New York
$2.56K +$3.39K +202 New
Fidelity Investments
39
Fidelity Investments
Massachusetts
$1.55K +$2.05K +122 New
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
– -$545K -42,444 Closed
Two Sigma Investments
41
Two Sigma Investments
New York
– -$248K -21,534 Closed
Millennium Management
42
Millennium Management
New York
– -$226K -19,639 Closed
1
2

ACRV Hedge Fund Activity: Q1 2023 in Review

39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2023, worth a combined $191M — up 12% from $170M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ACRV positions and 3 closed out — a net gain of 22 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $7.96M. The largest seller was Marshall Wace, cutting an estimated $10.5M.

  • 39 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2023, up from 18 in Q4 2022.
  • Funds reported $191M of Acrivon Therapeutics stock for Q1 2023, up 12% quarter-over-quarter.
  • 25 funds opened new Acrivon Therapeutics positions in Q1 2023 and 3 closed out, a net change of +22 holders.
  • The largest Acrivon Therapeutics buyer in Q1 2023 was BlackRock, an estimated $7.96M added.
  • The largest Acrivon Therapeutics seller in Q1 2023 was Marshall Wace, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2023.